Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Wholesalers' FY2003 Results Could Be Worse than FY2001's: Mr Kimura
October 27, 2003
- WG to Select OTC Drugs "With No Particular Problems in Regard to Safety"
October 27, 2003
- More Pharma Companies Outsourcing Call Center Work: Bell System 24
October 27, 2003
- Inauguration of Insurance Pharmacy Association Expected Next Spring
October 27, 2003
- Domain Associates Announce Novel Licensing Agreements with Takeda, Kyowa Hakko
October 27, 2003
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
October 27, 2003
- BUSINESS NEWS IN BRIEF
October 27, 2003
- MEDICAL DEVICE NEWS IN BRIEF
October 27, 2003
- BULLETIN
October 27, 2003
- DIAGNOSTIC NEWS IN BRIEF
October 27, 2003
- WEBSITE NEWS
October 27, 2003
- Most GE Houses Forecast Growth in FY2003: EPMA Survey
October 27, 2003
- ＜Special Contribution＞
October 27, 2003
- Import Approval for Evista, Precedex Recommended
October 27, 2003
- Pricing of Long-listed Drugs Discussed by Chuikyo Subpanel
October 27, 2003
- Korosho to Widen Selection Criteria for Priority NDA Review
October 27, 2003
- REGULATORY NEWS IN BRIEF
October 27, 2003
- Developing Something Like a Niche: Dr Matsuda of Kyowa Hakko
October 27, 2003
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 27, 2003
- WORLD NEWS IN BRIEF
October 27, 2003
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…